CBS 2019
CBSMD教育中心
中 文

旋磨术

Abstract

Recommended Article

North American Expert Review of Rotational Atherectomy Procedural Success and Outcomes With Increasing Use of Enabling Strategies for Chronic Total Occlusion Intervention Orbital atherectomy for the treatment of small (2.5mm) severely calcified coronary lesions: ORBIT II sub-analysis Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation Trends in Usage and Clinical Outcomes of Coronary Atherectomy: A Report From the National Cardiovascular Data Registry CathPCI Registry Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II) State of the art: evolving concepts in the treatment of heavily calcified and undilatable coronary stenoses - from debulking to plaque modification, a 40-year-long journey Temporal changes in radial access use, associates and outcomes in patients undergoing PCI using rotational atherectomy between 2007 and 2014: results from the British Cardiovascular Intervention Society national database

Original Research

JOURNAL:CBSMD Article Link

紫杉醇涂层球囊的最新研究进展

CBSMD

Pre-reading

支架内再狭窄仍是个临床难题,紫杉醇涂层球囊(Paclitaxel-coated balloons,PCBs)不失为一种替代方案。以下为PCBs的最新研究证据:


2019年1月新鲜出炉的Clinical and angiographic outcomes of coronary dissection after paclitaxel-coated balloon angioplasty for small vessel coronary artery disease纳入了单中心 2.8mm的小冠脉血管病变,试图解释PCB即可经造影明确的冠脉夹层的发生机制及分型,并开展了术后长于6个月的临床随访,以进一步观察冠脉夹层的进展。


Optical Coherence Tomography Predictors for Recurrent Restenosis After Paclitaxel-Coated Balloon Angioplasty for Drug-Eluting Stent Restenosis”介绍了PCB-Angioplasty治疗DES-ISR后复发再狭窄的OCT影像学发现,6个月后发生复发再狭窄病变处的组织异质性更高,再狭窄病变处的最小官腔、支架面积、支架膨胀程度等指标显著不足。


Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study”比较了3年PEB和DES在治疗BMS-ISR的长期疗效。


德国亚琛Schröder等回顾性完成了两种PCB术后一年MACE的比较分析“Long-term clinical outcomes after treatment of stent restenosis with two drug-coated balloons采用单中心、非随机设计回顾性获取了单中心两种PCBs一年的MACE事概率(15.0 and 15.8% (P=0.879) for the BTHC-PCB and iopromide-based PCB groups)和1TLR、心梗、心源性死事件概率(分别为9.6 versus 11.8%, P=0.622; 5.3 versus 3.9%, P=0.640; and 5.3 versus 3.9%, P=0.640)。


Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis: A pooled analysis of the Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4 trial”比较了PCB两种药用辅料BTHC-PCB (n=127) iopromide-PCBn=137)置入6-8个月随访造影终点和1年临床终点。


Therapeutic efficacy of paclitaxel-coated balloon for de novo coronary lesions with diameters larger than 2.8 mm前瞻性地对以2.8mm为血管直径为分组阈值,在238例原发病变中评价紫杉醇涂层球囊的安全性和有效性。